Mensicectomy is no better than sham surgery??? What the NEJM Study on Meniscus Surgery Actually Means for Patients

A new report in the New England Journal of Medicine has reignited a debate that has simmered in orthopedic circles for more than a decade: does removing a torn piece of meniscus actually help, or is the entire procedure built on a foundation of wishful thinking? The paper, a 10-year follow-up of the landmark FIDELITY trial, is already being framed in some corners of the internet as proof that partial meniscectomy is a waste of an operating room slot. That framing misses the more useful, and more honest, story the data actually tells.

The Study Behind the Headlines

The FIDELITY trial (Finnish Degenerative Meniscal Lesion Study) began in 2007 as one of the more rigorous experiments ever run on a common orthopedic procedure. Investigators in Finland randomized 146 adults, ages 35 to 65, who had knee pain from a degenerative medial meniscus tear and no radiographic osteoarthritis, to either arthroscopic partial meniscectomy (APM) or a sham surgery: a real trip to the operating room, real anesthesia, and a real skin incision, but no actual removal of meniscal tissue (Sihvonen et al., N Engl J Med, 2013). Patients did not know which group they were in. Neither did the physical therapists tracking their recovery.

The original 2013 results showed no meaningful difference between the two groups at two years. Both groups improved. Both groups were largely satisfied. That finding alone was enough to shake the confidence of surgeons who had spent careers performing this operation on the assumption that cutting out damaged tissue must help.

Now the same research group has published the 10-year data (Kalske et al., N Engl J Med, 2026). Of the original 146 patients, 133 (91 percent) were tracked down a full decade later, an unusually strong retention rate for orthopedic research. The results, on their face, look like more bad news for APM.

What the Numbers Actually Show

At 10 years, the sham surgery group scored better on the WOMET instrument, which measures meniscal symptoms and disability, by 9.4 points, a difference that reached statistical significance (98.33% CI, -17.0 to -1.7). Knee function scores (Lysholm) and pain after exercise trended in the same direction but did not reach statistical significance. Radiographic osteoarthritis progressed in 81 percent of the meniscectomy group versus 70 percent of the sham group, a 12-point difference that also did not cross the threshold for statistical significance (95% CI, -1 to 26). Eight meniscectomy patients (13 percent) eventually needed a knee replacement or osteotomy, compared with three (4 percent) in the sham group.

The authors' own conclusion is blunt: they found no evidence of benefit from APM and a suggestion of worse outcomes, and they argue this raises concern about using the procedure for degenerative meniscal tears in middle-aged and older adults.

That is a fair reading of their data, and it deserves to be stated plainly rather than argued away. But a careful look at the numbers, and at who was actually enrolled in this trial, tells a more nuanced clinical story than the headline conclusion suggests.

Reading Between the Confidence Intervals

Two things stand out. First, the only outcome that reached statistical significance, the WOMET score, is worth putting in context. Published minimal clinically important difference thresholds for WOMET run in the range of 15 to 20 points depending on the population studied. A 9.4-point gap between groups is real on paper, but it sits below the level most researchers consider large enough for a patient to actually notice in daily life. Statistically significant is not the same as clinically significant, and that distinction matters enormously when translating a trial result into advice for an individual patient.

Second, and more importantly for how this study should be used in clinical decision-making, the radiographic osteoarthritis progression difference, the finding most likely to frighten a patient out of a reasonable operation, did not reach statistical significance over 10 years of follow-up. An 81 percent versus 70 percent split sounds dramatic until the confidence interval is examined: it spans from a 1-point advantage for meniscectomy to a 26-point disadvantage. That is a wide, uncertain range built on a small trial (64 surgical patients, 69 sham patients at final follow-up). It is a signal worth taking seriously and watching in future, larger studies. It is not proof that meniscectomy accelerates arthritis in a way that should override a patient's current, day-to-day pain.

This is also a highly selected population. FIDELITY specifically excluded patients with any radiographic knee osteoarthritis at baseline and excluded anyone with a recent traumatic injury. The trial was, by its own investigators' design, built to give APM its best chance to demonstrate benefit in a population least likely to have confounding joint damage. That is a scientifically sound way to isolate the effect of meniscus removal, but it also means the trial answers a narrower question than the headlines suggest: does removing a degenerative tear help patients who have minimal underlying arthritis, compared with a placebo operation? It says considerably less about the far larger population of patients who have already tried physical therapy, anti-inflammatories, and activity modification, and are still in pain.

The Practical Takeaway

Nothing in this trial, or in the broader literature on meniscal surgery (Katz et al., N Engl J Med, 2013; Englund, Acta Orthop Scand Suppl, 2004), changes a core principle that should guide every conversation about this operation: the meniscus is a biologically important structure. It distributes load across the knee joint, absorbs shock, and helps protect the cartilage underneath it (Mameri et al., Curr Rev Musculoskelet Med, 2022). A patient with a meniscal tear who is not experiencing meaningful pain has no business having tissue removed on the theory that it might eventually cause trouble. Surgery should never be offered as a preventive measure against a problem the patient does not yet have.

But that is a different clinical scenario from the patient sitting in an exam room today, months into physical therapy, still limited by mechanical knee pain from a degenerative tear that has not responded to conservative care. For that patient, this 10-year data is, if anything, reassuring rather than damning. The trial shows that patients who underwent meniscectomy did not end up statistically worse off in terms of arthritis progression than patients who lived with an untreated tear for a decade. Pain relief and satisfaction rates were comparable between groups at the study's endpoint. In other words, the fear that meniscectomy will trade short-term pain relief for long-term joint destruction is not supported at a level of statistical confidence that should drive decision-making away from surgery when nonoperative treatment has already failed.

The 2024 AAOS clinical practice guideline on meniscal pathology reaches a similar, more moderate conclusion: patients who fail a reasonable trial of nonoperative treatment may do better with surgical intervention, and when surgery is performed, preserving as much functional meniscal tissue as possible remains the priority.

The Bottom Line

This study does not validate meniscectomy as a first-line treatment, and it should not be read that way. It also does not support treating partial meniscectomy as an obsolete or harmful procedure for the right patient. Patients without significant pain should keep their meniscus. Patients who have exhausted physical therapy, activity modification, and time, and remain limited by pain from a degenerative tear, can be counseled honestly: partial meniscectomy is likely to relieve their current symptoms, and a decade of rigorous, sham-controlled data does not show a statistically significant increase in arthritis risk compared with living with the tear untreated. That is a more measured conclusion than either the enthusiastic surgeon of a generation ago or today's headline writer would offer, but it is the conclusion the actual numbers support.